Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells

Current Pharmaceutical Design

Volumn 19, Issue 15, 2013, Pages 2765-2770

  Tibullo, Daniele ^a   Barbagallo, Ignazio ^a   Giallongo, Cesarina ^a   La Cava, Piera ^a   Parrinello, Nunziatina ^a   Vanella, Luca ^a   Stagno, Fabio ^a   Palumbo, Giuseppe A ^a   Li Volti, Giovanni ^a,b   Di Raimondo, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Istituto Euro Mediterraneo di Scienza e Tecnologia IEMEST   (Italy)

Author keywords

Chronic myeloid leukemia; Heme oxygenase; Imatinib; Nuclear traslocation

Indexed keywords

ACETYLCYSTEINE; BILIRUBIN; CARBON MONOXIDE; HEME OXYGENASE 1; HEMIN; IMATINIB; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL PROTECTION; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HEME OXYGENASE-1; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; REACTIVE OXYGEN SPECIES;

EID: 84876712355     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319150012     Document Type: Article

References (28)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
2. Sawyers CL, Druker B. Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J Sci Am 1999; 5: 63-69.
3. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
4. Litzow MR. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med 2006; 130: 669-679.
5. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
6. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
7. Mayerhofer M, Gleixner KV, Mayerhofer J, et al. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008; 111: 2200-2210.
8. Mayerhofer M, Florian S, Krauth MT, et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res 2004; 64: 3148-3154.
9. Barbagallo I, Marrazzo G, Frigiola A, Zappala A, Li Volti G. Role of carbon monoxide in vascular diseases. Curr Pharm Biotechnol 2012; 13: 787-796.
10. Alcaraz MJ, Fernandez P, Guillen MI. Anti-inflammatory actions of the heme oxygenase-1 pathway. Curr Pharm Des 2003; 9: 2541-2551.
11. Pae HO, Oh GS, Choi BM, Chae SC, Chung HT. Differential expressions of heme oxygenase-1 gene in CD25- and CD25+ subsets of human CD4+ T cells. Biochem Biophys Res Commun 2003; 306: 701-705.
12. Fang J, Sawa T, Akaike T, et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 2003; 63: 3567-3574.
13. Rushworth SA, MacEwan DJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008; 111: 3793-3801.
14. Tanaka S, Akaike T, Fang J, et al. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br J Cancer 2003; 88: 902-909.
15. Motterlini R, Mann BE, Foresti R. Therapeutic applications of carbon monoxide-releasing molecules. Expert Opin Investig Drugs 2005; 14: 1305-1318.
16. Hadzijusufovic E, Rebuzzi L, Gleixner KV, et al. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Exp Hematol 2008; 36: 1461-1470.
17. Singh MM, Irwin ME, Gao Y, et al. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer 2011.
18. Rakshit S, Bagchi J, Mandal L, et al. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide. Apoptosis 2009; 14: 298-308.
19. Juhasz A, Ge Y, Markel S, et al. Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic Res 2009; 43: 523-532.
20. Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717-1723.
21. Nieborowska-Skorska M, Kopinski PK, Ray R, et al. Rac2-MRCcIII- generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012; 119: 4253-4263.
22. Giallongo C, Tibullo D, La Cava P, et al. BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. Acta Haematol 2011; 126: 205-210.
23. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-4022.
24. Flis K, Irvine D, Copland M, Bhatia R, Skorski T. Chronic myeloid leukemia stem cells display alterations in the expression of genes involved in oxidative phosphorylation. Leuk Lymphoma 2012.
25. Lin Q, Weis S, Yang G, et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J Biol Chem 2007; 282: 20621-20633.
26. Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw 2005; 3: 757-768.
27. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
28. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.